L Catterton, a consumer-focused private equity firm, has led a Series B round for Trautec, a China-based biotech start-up that develops synthetic proteins used in beauty and healthcare products.
The round raised RMB 200 million ($27 million) and was also participated by CDF-Capital and MF Capital. Trautec is a pioneer and market leader in China’s synthetic recombinant human collagen (SRHC) industry.
Brahmal Vasudevan (former alumini of King’s and therefore probably a local ) is a Malaysian private equity investor who has been dubbed the “Midas Touch” for his ability to turn investments into gold. Brahmal Vasudevan Net Worth Brahmal is the…
In a significant boost to sustainable transportation, HumanForest, a UK-based micromobility startup, has successfully raised €5.7 million in a Series A funding extension. This brings the company’s total Series A…
The German Football League (DFL) is exploring new financial horizons, entertaining the possibility of a substantial private equity injection into the Bundesliga, Germany’s premier football competition. With a goal to…
L Catterton is a global private equity firm that specializes in consumer-focused investments. With over $22 billion of equity capital across six fund strategies in 17 offices globally,
L Catterton invests in companies that operate in the consumer goods and services sector. The firm has a long history of investing in companies that have strong brand recognition, high growth potential, and a proven track record of success.
Private Equity News Asia
Trautec: A Brief Overview
Trautec is a Guangzhou-based biotech start-up that specializes in the development of synthetic proteins used in beauty and healthcare products. Trautec is a pioneer and market leader in China’s synthetic recombinant human collagen industry. The company’s products are used in a wide range of applications, including wound healing, tissue engineering, and cosmetic surgery.
L Catterton’s recent investment in Trautec is part of a larger trend of private equity firms investing in the biotech and healthcare sectors.
The $27 million Series B fundraise led by L Catterton will help Trautec expand its product portfolio and accelerate its growth in the rapidly expanding global market for beauty and healthcare products featuring synthetic recombinant human collagen.
The partnership between L Catterton and Trautec is expected to create synergies that will benefit both companies. L Catterton’s extensive experience in the consumer goods and services sector will help Trautec expand its reach and develop new products that meet the needs of consumers. At the same time, Trautec’s innovative products and technology will help L Catterton’s portfolio companies stay ahead of the curve in an increasingly competitive market.
Overall, the partnership between L Catterton and Trautec is a win-win for both companies.
L Catterton’s investment will help Trautec achieve its growth objectives, while Trautec’s innovative products will help L Catterton’s portfolio companies stay ahead of the curve in the rapidly evolving consumer goods and services sector.
Series B Fundraise
L Catterton has led a Series B round for Trautec, a China-based biotech start-up that develops synthetic proteins used in beauty and healthcare products.
The consumer-focused private equity firm is investing via its debut renminbi fund, which is targeting CNY 2bn and hit a first close last year, reportedly collecting CNY 1bn.
Trautec has completed a RMB 200 million ($27 million) Series B fundraise led by L Catterton, a leading global consumer-focused investment firm. The company is a pioneer and market leader in China’s synthetic recombinant human collagen industry. Trautec’s proprietary technology platform enables the production of high-quality, cost-effective, and scalable SRHC, which is used in a wide range of applications, including skincare, wound healing, and tissue engineering.
The Series B fundraise will enable Trautec to accelerate its growth and expand its product offerings.
The company plans to use the funds to enhance its manufacturing capabilities, strengthen its research and development capabilities, and expand its sales and marketing efforts. The investment will also help Trautec to establish itself as a global leader in the SRHC industry.
The Series B fundraise is a significant milestone for Trautec, as it demonstrates the company’s ability to attract high-quality investors and build a strong foundation for future growth.
The investment will provide Trautec with the equity capital it needs to execute on its strategic plan and achieve its long-term goals. With the support of L Catterton and other investors, Trautec is well-positioned to capitalize on the rapidly growing demand for SRHC and other synthetic proteins.
The Role of Synthetic Recombinant Human Collagen
Synthetic Recombinant Human Collagen (SRHC) is a type of synthetic protein that is used in a variety of medical and cosmetic applications.
It is a man-made version of the natural collagen protein found in the human body. SRHC is produced by genetically engineering bacteria to produce collagen that is identical to human collagen.
SRHC in Medical Technology
SRHC has many potential applications in medical technology. It can be used to create scaffolds for tissue engineering, as well as for wound healing and drug delivery. SRHC is also being studied as a potential treatment for a variety of medical conditions, including osteoarthritis, spinal cord injuries, and heart disease.
One of the advantages of SRHC is that it can be tailored to specific applications. Different types of collagen, such as Type I, Type II, Type III, and Type XVII, can be produced depending on the intended use.
This allows for greater flexibility in the development of medical devices and therapies.
SRHC in Beauty and Healthcare Products
SRHC is also used in a range of beauty and healthcare products.
It is commonly found in anti-aging creams, as it can help to improve skin elasticity and reduce the appearance of fine lines and wrinkles. SRHC is also used in hair care products, as it can help to strengthen hair and prevent breakage.
The SRHC industry has seen significant growth in recent years, with companies such as Trautec leading the way in the development and production of synthetic collagen.
Trautec’s recent Series B fundraise, led by L Catterton, is a testament to the potential of this technology.
Overall, SRHC has a wide range of potential applications in both medical technology and beauty and healthcare products. As the industry continues to grow and evolve, it is likely that we will see even more innovative uses for this versatile synthetic protein.
Trautec’s Position in the Market
Trautec’s Growth and Expansion
Trautec Medical Technology is a pioneer and market leader in China’s synthetic recombinant human collagen (SRHC) industry.
The company has recently completed a RMB 200 million ($27 million) Series B fundraise led by L Catterton, a leading global consumer-focused investment firm. This investment is expected to help Trautec accelerate its growth and expansion plans.
Trautec has experienced significant growth since its inception, and the company is well-positioned to continue this trend.
The global synthetic recombinant human collagen market is expected to reach $186 billion by 2028, and Trautec is at the forefront of this rapidly expanding market.
Trautec’s First-Mover Advantages
One of Trautec’s key advantages is its first-mover status in the SRHC industry. The company has developed a proprietary technology platform that allows it to produce high-quality, cost-effective SRHC products.
This technology gives Trautec a significant competitive advantage over other companies in the market.
Furthermore, Trautec has established strong relationships with leading beauty and healthcare companies in China and internationally. These partnerships have helped Trautec to expand its customer base and increase its market share.
Overall, Trautec is in a pole position to capitalise on the growing demand for SRHC products in China and globally. With the support of L Catterton, Trautec is well-positioned to continue its growth and expansion plans in the coming years.
Consumer-Focused Products and Services
L Catterton’s investment in Trautec reflects the private equity firm’s focus on consumer-focused products and services.
Trautec is a pioneer and market leader in China’s synthetic recombinant human collagen (SRHC) industry, which is poised for further growth in the global market for beauty and healthcare products featuring synthetic recombinant.
Consumers are increasingly seeking out products that are tailored to their specific needs and preferences.
Trautec’s products are designed to meet these needs, providing a high-quality, safe, and effective alternative to traditional collagen products. The company’s focus on innovation and technology has enabled it to develop a range of products that are both effective and affordable.
L Catterton’s investment in Trautec is a clear indication of the private equity firm’s confidence in the company’s ability to meet the evolving needs of consumers. The investment will enable Trautec to expand its operations and develop new products that are tailored to the specific needs of consumers.
Overall, L Catterton’s focus on consumer-focused products and services reflects the growing importance of meeting consumers’ increasing preferences.
Trautec’s innovative products and focus on technology are well-positioned to meet these needs, and L Catterton’s investment will enable the company to continue to grow and expand its operations in the years to come.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.